» Articles » PMID: 39677631

Alpha-synuclein Knockout Impairs Melanoma Development and Alters DNA Damage Repair in the TG3 Mouse Model in a Sex-dependent Manner

Overview
Journal bioRxiv
Date 2024 Dec 16
PMID 39677631
Authors
Affiliations
Soon will be listed here.
Abstract

Strong evidence suggests links between Parkinson's Disease (PD) and melanoma, as studies have found that people with PD are at an increased risk of developing melanoma and those with melanoma are at increased risk of developing PD. Although these clinical associations are well-established, the cellular and molecular pathways linking these diseases are poorly understood. Recent studies have found a previously unrecognized role for the neurodegeneration-associated protein alpha-synuclein (αSyn) in melanoma; the overexpression of αSyn promotes melanoma cell proliferation and metastasis. However, to our knowledge, no studies have investigated the role of αSyn in melanoma models outside of a xenograft paradigm. Our study created and characterized knockout in the spontaneously developing melanoma TG3 mouse line, TG3+/+-/-. We show that αSyn loss-of-function significantly delays melanoma onset and slows tumor growth . Furthermore, decreased tumor volume is correlated with a decreased DNA damage signature and increased apoptotic markers, indicating a role for αSyn in modulating the DNA damage response (DDR) pathway. Overall, our study provides evidence that targeting αSyn and its role in modulating the DDR and melanomagenesis could serve as a promising new therapeutic target.

References
1.
Shrivastav M, De Haro L, Nickoloff J . Regulation of DNA double-strand break repair pathway choice. Cell Res. 2007; 18(1):134-47. DOI: 10.1038/cr.2007.111. View

2.
Berthenet K, Castillo Ferrer C, Fanfone D, Popgeorgiev N, Neves D, Bertolino P . Failed Apoptosis Enhances Melanoma Cancer Cell Aggressiveness. Cell Rep. 2020; 31(10):107731. DOI: 10.1016/j.celrep.2020.107731. View

3.
Joosse A, Collette S, Suciu S, Nijsten T, Patel P, Keilholz U . Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013; 31(18):2337-46. DOI: 10.1200/JCO.2012.44.5031. View

4.
Lo R, Tanner C, Van Den Eeden S, Albers K, Leimpeter A, Nelson L . Comorbid cancer in Parkinson's disease. Mov Disord. 2010; 25(12):1809-17. DOI: 10.1002/mds.23246. View

5.
Schiffner S, Chen S, Becker J, Bosserhoff A . Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases. Exp Dermatol. 2012; 21(10):786-8. DOI: 10.1111/j.1600-0625.2012.01560.x. View